KemPharm uses its LAT platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
KMPH (Common Stock)
06/23/17 4:00 p.m. ET
KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids
KemPharm Announces Addition to Leadership Team
KemPharm, Inc. Reports First Quarter 2017 Results
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.
View Attributions and Sources